Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors.

Genome Med 2018 10 31;10(1):81. Epub 2018 Oct 31.

Princess Margaret Cancer Centre, University Health Network, 610 University Avenue, Toronto, Ontario, M5G 2M9, Canada.

Background: Patients diagnosed with high-grade serous ovarian cancer (HGSOC) who received initial debulking surgery followed by platinum-based chemotherapy can experience highly variable clinical responses. A small percentage of women experience exceptional long-term survival (long term (LT), 10+ years), while others develop primary resistance to therapy and succumb to disease in less than 2 years (short term (ST)). To improve clinical management of HGSOC, there is a need to better characterize clinical and molecular profiles to identify factors that underpin these disparate survival responses.

Methods: To identify clinical and tumor molecular biomarkers associated with exceptional clinical response or resistance, we conducted an integrated clinical, exome, and transcriptome analysis of 41 primary tumors from LT (n = 20) and ST (n = 21) HGSOC patients.

Results: Younger age at diagnosis, no residual disease post debulking surgery and low CA125 levels following surgery and chemotherapy were clinical characteristics of LT. Tumors from LT survivors had increased somatic mutation burden (median 1.62 vs. 1.22 non-synonymous mutations/Mbp), frequent BRCA1/2 biallelic inactivation through mutation and loss of heterozygosity, and enrichment of activated CD4+, CD8+ T cells, and effector memory CD4+ T cells. Characteristics of ST survival included focal copy number gain of CCNE1, lack of BRCA mutation signature, low homologous recombination deficiency scores, and the presence of ESR1-CCDC170 gene fusion.

Conclusions: Our findings suggest that exceptional long- or short-term survival is determined by a concert of clinical, molecular, and microenvironment factors.

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13073-018-0590-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208125PMC
October 2018
39 Reads
4.942 Impact Factor

Publication Analysis

Top Keywords

clinical molecular
8
high-grade serous
8
serous ovarian
8
clinical
8
ovarian cancer
8
debulking surgery
8
long- short-term
8
exceptional long-
8
low ca125
4
post debulking
4
surgery low
4
residual disease
4
younger age
4
patientsresults younger
4
age diagnosis
4
diagnosis residual
4
ca125 levels
4
disease post
4
chemotherapy clinical
4
increased somatic
4

Altmetric Statistics

References

(Supplied by CrossRef)

DD Bowtell et al.
Nat Rev Cancer 2015

S Lheureux et al.
Cancer 2015

RD Cress et al.
Obstet Gynecol 2015

F Dao et al.
Gynecol Oncol 2016

JR McLaughlin et al.
J Natl Cancer Inst 2013

J Ledermann et al.
Lancet Oncol. 2014

N De Picciotto et al.
Crit Rev Oncol Hematol 2016

TV Gorodnova et al.
Cancer Lett 2015

E Sato et al.
Proc Natl Acad Sci U S A 2005

JR Webb et al.
Clin Cancer Res. 2014

Similar Publications